Recent Updates
Recently added Catalysts
IVA Neutral Sentiment Score: 55/100

Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC Instructions to The Bank of New York, as Depositary (Must be received prior to 12:00 PM Eastern Time

Key Takeaway: The article details the instructions for formalizing the vote process for the upcoming Ordinary & Extraordinary General Meeting of Shareholders for Inventiva S.A. It outlines the necessary steps shareholders must take to ensure their votes are counted, including signing the Proxy/Vote Form and the conditions under which the Board of Directors may increase share capital. Additionally, it mentions upcoming agenda items such as the approval of compensation policies for directors, share buyback authorizations, and the renewal of certain director mandates. Specific legal articles from the French Commercial Code are referenced to reinforce the company's compliance and governance.

Market Sentiment Analysis

Full Press Release Details

Power for formalities. #P40# #P40# #P40# Proposal_Page - VIFL Authorized Signatures - Must be completed for your instructions to be executed. Please sign exactly as your name(s) appears on your account. If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the Proxy/Vote Form.
Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums; #P36# #P36# #P36# 35. Decision to be taken in application of article L. 225-248 of the French Commercial Code (shareholders' equity less than half the share capital); #P37# #P37# #P37# 36. Harmonization of the articles of association of the Company with applicable laws and regulations, including some provisions of the French Law no. 2024-537 of June 13, 2024 aimed at increasing business financing and France's attractiveness; #P38# #P38# #P38# On an ordinary basis 37.
Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights; #P35# #P35# #P35# 34.
Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company; #P33# #P33# #P33# 32. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind within the limits set by legal and regulatory provisions, excluding the case of a public exchange offer initiated by the Company; #P34# #P34# #P34# 33.
If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the Proxy/Vote Form. Signature (and Title if applicable) Date Signature (if held jointly) Date Inventiva S.A. Ordinary & Extraordinary General Meeting of Shareholders Please make your marks like this: PROPOSAL YOUR VOTE FOR AGAINST ABSTAIN 31.
Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders' preemptive subscription rights; #P32# #P32# #P32# Proposal_Page - VIFL Authorized Signatures - Must be completed for your instructions to be executed. Please sign exactly as your name(s) appears on your account.
Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the U.S. market called "At-the-market" or "ATM", without shareholders' preemptive subscription rights; #P31# #P31# #P31# 30.
Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in favor of one or more persons specifically designated by the Board of Directors, without shareholders' preemptive subscription rights; #P30# #P30# #P30# 29.
Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders' preemptive subscription rights; #P29# #P29# #P29# 28.
Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders' preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1 of the French Code mon taire et financier; #P28# #P28# #P28# 27.
Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders' preemptive subscription rights maintained; #P26# #P26# #P26# 25. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders' preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2- 1 of the French Code mon taire et financier; #P27# #P27# #P27# 26.
Renewal of the Director's mandate of Mr. Fr d ric Cren; #P21# #P21# #P21# 21. Renewal of the Director's mandate of Cell+; #P22# #P22# #P22# 22. Authorization granted to the Board of Directors to buyback the Company's shares; #P23# #P23# #P23# Extraordinary items 23. Authorization to the Board of Directors to reduce the share capital by cancellation of shares; #P25# #P25# #P25# 24.
Ordinary & Extraordinary General Meeting of Shareholders Please make your marks like this: PROPOSAL YOUR VOTE FOR AGAINST ABSTAIN 17. Total compensation paid to members of the Board of Directors; #P18# #P18# #P18# 18. Approval of the compensation policy of the Company's directors; #P19# #P19# #P19# 19. Appointment of Ms. Ren e Aguiar-Lucander, as Director of the Company; #P20# #P20# #P20# 20.
Please sign exactly as your name(s) appears on your account. If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the Proxy/Vote Form. Signature (and Title if applicable) Date Signature (if held jointly) Date Inventiva S.A.
Mark Pruzanski in his capacity as Chairman of the Board of Directors; #P15# #P15# #P15# 15. Approval of the compensation policy for Mr. Fr d ric Cren in his capacity as Chief Executive Officer; #P16# #P16# #P16# 16. Approval of the compensation policy for Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer; #P17# #P17# #P17# Proposal_Page - VIFL Authorized Signatures - Must be completed for your instructions to be executed.
Pierre Broqua in his capacity as Deputy Chief Executive Officer for the financial year ended December 31, 2024; #P13# #P13# #P13# 13. Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code; #P14# #P14# #P14# 14. Approval of the compensation policy for Mr.
Final approval of the fixed and variable compensation paid or awarded to Mr. Fr d ric Cren in his capacity as Chairman of the Board of Directors and Chief Executive Officer until December 13, 2024 and as Chief Executive Officer from December 13, 2024 for the financial year ended December 31, 2024; #P12# #P12# #P12# 12. Final approval of the fixed and variable compensation paid or awarded to Mr.
Approval of the subscription agreement for pre-funded warrants issued by the Company signed on December 13, 2024 between the Company and Samsara BioCapital L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code; #P10# #P10# #P10# 10. Final approval of the fixed and variable compensation paid or awarded to Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors for the financial year ended December 31, 2024 (from December 13, 2024); #P11# #P11# #P11# 11.
Approval of the transfer of know-how and communication agreement signed on December 11, 2024 between the Company and its Deputy Chief Executive Officer, in accordance with Articles L.225-38 et seq. of the French Commercial Code; #P8# #P8# #P8# 8. Approval of the subscription agreement for new shares issued by the Company signed on December 13, 2024 between the Company and Samsara BioCapital L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code; #P9# #P9# #P9# 9.
Approval of the subscription agreement for royalty certificates issued by the Company signed on July 17, 2024 between the Company and Biotechnology Value Fund Partners L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code; #P6# #P6# #P6# 6. Approval of the subscription agreement for new shares and pre-funded warrants issued by the Company signed on October 17, 2024 between the Company and Biotechnology Value Fund Partners L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code; #P7# #P7# #P7# 7.
Approval of the statutory financial statements for the financial year ended December 31, 2024; #P2# #P2# #P2# 2. Approval of the consolidated financial statements for the financial year ended December 31, 2024; #P3# #P3# #P3# 3. Appropriation of profit/loss for the financial year ended December 31, 2024; #P4# #P4# #P4# 4. Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code; #P5# #P5# #P5# 5.
PLEASE VOTE BY: 12:00 PM, Eastern Time, May 15, 2025 Have your ballot ready and please use one of the methods below for easy voting: Your vote matters! Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Inventiva S.A. Ordinary & Extraordinary General Meeting of Shareholders Please make your marks like this: PROPOSAL YOUR VOTE Ordinary items FOR AGAINST ABSTAIN 1.
Inventiva S.A. PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDE Inventiva S.A. Ordinary & Extraordinary General Meeting of Shareholders For Shareholders of record as of April 14, 2025 Thursday, May 22, 2025 9:00 AM, Local Time BNY: PO BOX 505006, Louisville, KY 40233-5006 Mail: - Mark, sign and date your Proxy Card - Fold and return your Proxy Card in the postage-paid envelope provided YOUR VOTE IS IMPORTANT!
Notes: 1. Please direct the Depositary how to vote by placing an X in the box opposite the resolutions on the reverse side. 2. If no instructions are received, a discretionary proxy will be given to a person designated by the Company. 3. The Board recommends to vote for all resolutions except resolution #33. The Board recommends to vote against resolution #33.
Signature (and Title if applicable) Date Signature (if held jointly) Date

Frequently Asked Questions

What must be completed for instructions to be executed?

The VIFL Authorized Signatures section must be completed.

Do all joint tenants need to sign the Proxy/Vote Form?

Yes, all persons in joint tenancy must sign the form.

What happens if compensation policies are not approved?

The board may face challenges in aligning compensation with shareholder expectations.

Who signs the Proxy/Vote Form for a corporation?

The authorized officer signing must include their title and the corporation's full name.

What must directors include when signing as trustees?

Trustees must include their title and authority when signing.

Last updated: Apr 24, 2025